Crossmark Global Holdings’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.16M | Buy |
9,980
+19
| +0.2% | +$3.63K | 0.03% | 441 |
|
|
2026
Q1 | $1.83M | Sell |
9,961
-133
| -1% | -$24.5K | 0.03% | 455 |
|
|
2025
Q4 | $1.78M | Buy |
10,094
+6,436
| +176% | +$1.05M | 0.03% | 457 |
|
|
2025
Q3 | $512K | Sell |
3,658
-282
| -7% | -$38.1K | 0.01% | 890 |
|
|
2025
Q2 | $495K | Buy |
3,940
+338
| +9% | +$42.1K | 0.01% | 892 |
|
|
2025
Q1 | $493K | Sell |
3,602
-585
| -14% | -$83.6K | 0.01% | 879 |
|
|
2024
Q4 | $640K | Sell |
4,187
-2,870
| -41% | -$484K | 0.01% | 733 |
|
|
2024
Q3 | $1.37M | Sell |
7,057
-394
| -5% | -$82.4K | 0.02% | 513 |
|
|
2024
Q2 | $1.73M | Sell |
7,451
-1,807
| -20% | -$393K | 0.03% | 438 |
|
|
2024
Q1 | $2M | Sell |
9,258
-269
| -3% | -$63K | 0.04% | 422 |
|
|
2023
Q4 | $2.46M | Sell |
9,527
-2,255
| -19% | -$554K | 0.05% | 349 |
|
|
2023
Q3 | $3.11M | Sell |
11,782
-11,265
| -49% | -$3.01M | 0.07% | 289 |
|
|
2023
Q2 | $6.11M | Sell |
23,047
-835
| -3% | -$249K | 0.13% | 191 |
|
|
2023
Q1 | $6.64M | Buy |
23,882
+712
| +3% | +$197K | 0.16% | 170 |
|
|
2022
Q4 | $6.42M | Buy |
23,170
+4,602
| +25% | +$1.3M | 0.16% | 161 |
|
|
2022
Q3 | $4.96M | Buy |
18,568
+699
| +4% | +$148K | 0.14% | 186 |
|
|
2022
Q2 | $3.64M | Sell |
17,869
-319
| -2% | -$65.2K | 0.09% | 242 |
|
|
2022
Q1 | $3.83M | Buy |
18,188
+5,687
| +45% | +$1.24M | 0.09% | 255 |
|
|
2021
Q4 | $3M | Buy |
12,501
+2,555
| +26% | +$657K | 0.07% | 294 |
|
|
2021
Q3 | $2.81M | Buy |
9,946
+1,232
| +14% | +$404K | 0.07% | 295 |
|
|
2021
Q2 | $3.02M | Sell |
8,714
-1,371
| -14% | -$415K | 0.07% | 276 |
|
|
2021
Q1 | $2.82M | Sell |
10,085
-632
| -6% | -$170K | 0.07% | 288 |
|
|
2020
Q4 | $2.62M | Buy |
10,717
+195
| +2% | +$50.3K | 0.07% | 310 |
|
|
2020
Q3 | $2.98M | Sell |
10,522
-177
| -2% | -$49.4K | 0.08% | 254 |
|
|
2020
Q2 | $2.86M | Sell |
10,699
-675
| -6% | -$203K | 0.08% | 264 |
|
|
2020
Q1 | $3.6M | Sell |
11,374
-462
| -4% | -$140K | 0.13% | 184 |
|
|
2019
Q4 | $3.51M | Sell |
11,836
-2,307
| -16% | -$640K | 0.1% | 239 |
|
|
2019
Q3 | $3.29M | Sell |
14,143
-963
| -6% | -$224K | 0.1% | 240 |
|
|
2019
Q2 | $3.53M | Buy |
15,106
+946
| +7% | +$218K | 0.1% | 234 |
|
|
2019
Q1 | $3.35M | Sell |
14,160
-286
| -2% | -$90.1K | 0.1% | 248 |
|
|
2018
Q4 | $4.35M | Buy |
14,446
+743
| +5% | +$237K | 0.13% | 190 |
|
|
2018
Q3 | $4.84M | Sell |
13,703
-1,037
| -7% | -$357K | 0.12% | 202 |
|
|
2018
Q2 | $4.28M | Sell |
14,740
-1,706
| -10% | -$480K | 0.11% | 214 |
|
|
2018
Q1 | $4.5M | Buy |
16,446
+1,059
| +7% | +$329K | 0.12% | 216 |
|
|
2017
Q4 | $4.9M | Sell |
15,387
-1,133
| -7% | -$363K | 0.12% | 215 |
|
|
2017
Q3 | $5.17M | Buy |
+16,520
| New | +$4.89M | 0.13% | 189 |
|
|
2016
Q3 | $5.17M | Buy |
+16,520
| New | +$4.89M | 0.13% | 189 |
|
Other funds holding BIIB
Crossmark Global Holdings's BIIB Position: Q2 2026 in Review
Crossmark Global Holdings increased its Biogen (BIIB) stake by 0.19% in Q2 2026, buying an estimated $3.63K and bringing the position to 9,980 shares worth $2.16M. The position accounts for 0.03% of the portfolio, ranked #441.
Crossmark Global Holdings first reported a position in BIIB in Q3 2016 and has held it in 37 quarters since. The position peaked at $6.64M in Q1 2023. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Crossmark Global Holdings held 9,980 shares of Biogen worth $2.16M as of Q2 2026.
- Crossmark Global Holdings bought 19 Biogen shares in Q2 2026, an estimated $3.63K.
- Biogen made up 0.03% of Crossmark Global Holdings's portfolio in Q2 2026, its #441 holding.
- Crossmark Global Holdings first reported a position in Biogen in Q3 2016 and has held it in 37 quarters since.
- Crossmark Global Holdings's Biogen position peaked at $6.64M in Q1 2023.
- 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.